Stoke Therapeutics, Inc. 5,555,557 Shares of Common Stock and Pre-Funded Warrants to Purchase 3,703,730 Shares of Common Stock Underwriting AgreementStoke Therapeutics, Inc. • March 28th, 2024 • Pharmaceutical preparations • New York
Stoke Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), (i) an aggregate of 5,555,557 shares of common stock, par value $0.0001 per share, of the Company (the “Underwritten Shares”) and (ii) pre-funded warrants to purchase an aggregate of 3,703,730 shares of common stock of the Company, in a form to be mutually agreed by the Company and the Representative (the “Warrants”), and, at the option of the Underwriters, up to an additional 1,388,893 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Warrants are herein referred to as the “Underwritten Securities.” The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The Shares and the Warrants are herein referred to as the “Securities.” The shares of common stock issuable upon exercise of the
